Plasma lipoprotein(a) levels and risk of stroke recurrence among type 2 diabetes
2025-11-26
大量研究证实脂蛋白(a)[Lp(a)] 升高是ASCVD(包括冠心病、缺血性脑卒中、外围血管疾病及钙化性主动脉瓣狭窄等疾病)的独立危险因素[1]。Lp(a)已成为备受关注的血脂干预潜在新靶点之一。然而近年来大规模人群研究显示,糖尿病患者的Lp(a)水平低于非糖尿病患者,Lp(a)水平与糖尿病发病呈负相关。低Lp(a)浓度(小于bottom 10%)的患者其糖尿病患病风险增加27%[2]。同时有研究发现Lp(a)水平和胰岛素水平成负相关,具有较低Lp(a)水平的个体其胰岛素抵抗的程度增强[3,4]。基于此,我们提出了低水平Lp(a)降低ASCVD风险的优势会因增加2型糖尿病新发风险和胰岛素抵抗而被抵消。
The associations of Lp(a) with outcomes were examined using Cox regression model. Kaplan–Meier product limit method was used to generate survival plots, and the significance of differences between groups was tested by the log-rank test.